초록 ▼

A device for tissue engineering is formed of a porous bioabsorbable bag containing at least two bioabsorbable materials having different rates of bioabsorption such as beads of different degrading rates and a bioabsorbable binding gel such as fibrin that binds the bioabsorbable materials in relation

A device for tissue engineering is formed of a porous bioabsorbable bag containing at least two bioabsorbable materials having different rates of bioabsorption such as beads of different degrading rates and a bioabsorbable binding gel such as fibrin that binds the bioabsorbable materials in relation to each other. Slow degrading beads and the bag may be made of a copolymer of poly(L-lactide) and poly(glycolide), and fast degrading beads may be made of gelatin. The bag may contain cells and/or wound healing stimulants such as growth factors. Hydrolyzing enzymes may be used to enhance biodegradation of polymers. The device can be used to promote in-growth of host tissue into a void by inserting the bag with its contents into the void and conforming the bag to a desired shape. The binding gel may be injected into the bag after being placed in the void .

대표청구항 ▼

A device for tissue engineering is formed of a porous bioabsorbable bag containing at least two bioabsorbable materials having different rates of bioabsorption such as beads of different degrading rates and a bioabsorbable binding gel such as fibrin that binds the bioabsorbable materials in relation

A device for tissue engineering is formed of a porous bioabsorbable bag containing at least two bioabsorbable materials having different rates of bioabsorption such as beads of different degrading rates and a bioabsorbable binding gel such as fibrin that binds the bioabsorbable materials in relation to each other. Slow degrading beads and the bag may be made of a copolymer of poly(L-lactide) and poly(glycolide), and fast degrading beads may be made of gelatin. The bag may contain cells and/or wound healing stimulants such as growth factors. Hydrolyzing enzymes may be used to enhance biodegradation of polymers. The device can be used to promote in-growth of host tissue into a void by inserting the bag with its contents into the void and conforming the bag to a desired shape. The binding gel may be injected into the bag after being placed in the void . to about 5 hydrophobic groups per 100 monosaccharide units. 16. A parenteral vaccinal preparation comprising an antigen and an adjuvant, wherein the adjuvant comprises a hydrophobized polysaccharide having from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units and wherein the antigen is selected from tumor-associated antigens, viral antigens and autoantigen-reactive T-cell receptors. 17. The vaccinal preparation of claim 16, wherein the polysaccharide is selected from mannan and pullulan. 18. A method of immunization which comprises parenterally administering to a mammal a vaccinal preparation comprising hydrophobized polysaccharide and antigen. 19. The method of claim 18, wherein the antigen is capable of at least one of induction and activation of cytotoxic T-cells. 20. The method of claim 19, wherein the cytotoxic T-cell is antigen-specific. 21. The method of claim 18, wherein the hydrophobized polysaccharide comprises from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units. 22. The method of claim 18, wherein the hydrophobic groups are selected from alkyl groups and sterol residues. 23. The method of claim 22, wherein the sterol residues comprise a cholesterol residue. 24. The method of claim 18, wherein the antigen is selected from antigenic proteins having a molecular weight of from about 2,000 to about 100,000. 25. The method of claim 18, wherein the antigen comprises erbB-2 protein. 26. The method of claim 18, wherein the amount of antigen per administration is from about 50 to about 150 μg. 27. The method of claim 26, comprising from about one to about four administrations. 28. The method of claim 27, wherein the administration is subcutaneous. 29. A method of preventing a condition selected from a viral disease and an autoimmune disease, in a mammal, wherein the method comprises parenterally administering to said mammal a pharmaceutical preparation comprising hydrophobized polysaccharide and antigen. 30. A method of treating a condition selected from cancer, a viral disease and an autoimmune disease, in a mammal in need of such treatment, wherein the method comprises parenterally administering to said mammal an effective amount of a vaccinal preparation comprising hydrophobized polysaccharide and antigen. 31. The method of claim 30 wherein the condition is cancer. 32. A process for making a vaccinal preparation comprising a hydrophobized polysaccharide and an antigen, the process comprising mixing microparticles of aggregated hydrophobized polysaccharide and antigen and subjecting the resultant mixture to gel chromatography. 33. The process of claim 32, wherein said microparticles are made by a process comprising sonicating a solution of hydrophobized polysaccharide and filtering the sonicated solution through at least one membrane. 34. A vaccinal preparation comprising hydrophobized polysaccharide and antigen, wherein the hydrophobized polysaccharide comprises from about 0.9 to about 5 hydrophobic groups per 100 monosaccharide units and wherein the antigen is selected from tumor-associated antigens. 35. The vaccinal preparation of claim 34, wherein the hydrophobic groups are selected from alkyl groups and sterol residues. 36. The vaccinal preparation of claim 35, wherein the sterol residues comprise a cholesterol residue. 37. The vaccinal preparation of claim 34, wherein the hydrophobized polysaccharide comprises saccharide units whose primary hydroxyl group is represented by the following formula: --O--(CH2)mCONH(CH2)nNH--CO--O--R wherein R represents an alkyl group or a sterol residue; m represents 0 or 1; and n represents a positive integer. 38. The vaccinal preparation of claim 37, wherein the polysaccharide is selected from pullulan and mannan. 39. A process for making a pharmaceutical composition comprising at least one active ingredient, comprising combining the at least one active ingredient with an adjuvant, wherein the adju